Hope and Healing: Your Journey to Depression Recovery

We are proud to offer SPRAVATO® (esketamine), an FDA-approved nasal spray designed to help adults with treatment-resistant depression (TRD) or major depressive disorder (MDD). If traditional antidepressants haven’t provided the relief you need, SPRAVATO® may offer new hope for your recovery journey..

Spravato Treatment

SPRAVATO® in combination with an oral antidepressant

In a 4-week clinical study, patients were given either SPRAVATO® in combination with an oral antidepressant or a placebo nasal spray plus an oral antidepressant. The study showed:

  • Rapid and superior reduction in depression symptoms at ~4 weeks for more patients using SPRAVATO® in combination with an oral antidepressant, as compared with patients who received a placebo nasal spray plus an oral antidepressant*

  • Most of the reduction in depression symptoms was seen at 24 hours

  • Continued improvement between 24 hours and ~4 weeks; the difference in improvement between groups did not appear to increase through 4 weeks